Scholarlink

Background <p>Epithelial Membrane Protein 3 (EMP3) has been associated with multiple malignancies, but its expression patterns and clinical significance in acute myeloid leukemia (AML) remain poorly characterized.</p> Methods <p>Public datasets were integrated to assess EMP3 mRNA expression levels in AML patients versus healthy donors, with validation performed using reverse transcription quantitative PCR (RT-qPCR). Protein expression was accessed through immunohistochemistry. Prognosis relevance was evaluated via survival analysis. Molecular mechanisms were investigated using weighted gene co-expression network analysis (WGCNA), single-cell RNA sequencing, immune infiltration assessment, and pathway enrichment analysis.</p> Results <p>Elevated EMP3 expression was detected in AML samples relative to healthy donors, showing a standardized mean difference (SMD) of 0.84 (95% CI: 0.63, 1.05). This upregulation was validated by RT-qPCR and immunohistochemical analyses, yielding a consistent SMD of 0.94 (95% CI: 0.57, 1.32) when RT-qPCR data were included. Prognostic assessment indicated a significant association between EMP3 levels and AML clinical outcomes. Among 829 genes co-expressed with EMP3, enrichment was observed in acute myeloid leukemia-related pathways, with BCL2A1 and ITGAM identified as hub co-expressed genes.</p> Conclusion <p>These findings suggest that EMP3 overexpression occurs in AML and potentially influences disease prognosis.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Upregulation of EMP3 in acute myeloid leukemia: a study based on data mining, RT-qPCR and immunohistochemistry

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年9月2日

查看全文
  • Angui Liu,
  • Cong Yu,
  • Xianwei Peng,
  • Jiaodi Liu,
  • Yiting Zhang,
  • Yubing Ma,
  • Kanglai Wei,
  • Yinghui Lai

摘要

Background

Epithelial Membrane Protein 3 (EMP3) has been associated with multiple malignancies, but its expression patterns and clinical significance in acute myeloid leukemia (AML) remain poorly characterized.

Methods

Public datasets were integrated to assess EMP3 mRNA expression levels in AML patients versus healthy donors, with validation performed using reverse transcription quantitative PCR (RT-qPCR). Protein expression was accessed through immunohistochemistry. Prognosis relevance was evaluated via survival analysis. Molecular mechanisms were investigated using weighted gene co-expression network analysis (WGCNA), single-cell RNA sequencing, immune infiltration assessment, and pathway enrichment analysis.

Results

Elevated EMP3 expression was detected in AML samples relative to healthy donors, showing a standardized mean difference (SMD) of 0.84 (95% CI: 0.63, 1.05). This upregulation was validated by RT-qPCR and immunohistochemical analyses, yielding a consistent SMD of 0.94 (95% CI: 0.57, 1.32) when RT-qPCR data were included. Prognostic assessment indicated a significant association between EMP3 levels and AML clinical outcomes. Among 829 genes co-expressed with EMP3, enrichment was observed in acute myeloid leukemia-related pathways, with BCL2A1 and ITGAM identified as hub co-expressed genes.

Conclusion

These findings suggest that EMP3 overexpression occurs in AML and potentially influences disease prognosis.